Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01701895 · ClinicalTrials.gov registry record

Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera

A clinical trial of HIV-1-infection, sponsored by Prema Menezes, PhD, PA-C.

Completed
Registry status
33
Enrollment target
1
Study location

NCT01701895: Completed study of HIV-1-infection, sponsored by Prema Menezes, PhD, PA-C.

NCT01701895 is a study of HIV-1-infection that has completed, run by Prema Menezes, PhD, PA-C. The registered enrollment target is 33 participants, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01701895, a study of HIV-1-infection, has completed, sponsored by Prema Menezes, PhD, PA-C.

COMPLETED
Registry status
33 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to evaluate how easy it is for female HIV- positive subjects taking Complera to comply with the dietary requirement using a food diary in the short term (4 weeks) and long term (24 weeks and 48 weeks) and to determine association between calorie intake and virologic suppression. A secondary goal of the study is to evaluate subjects' attitudes towards contraception.

Primary Outcome

Compliance will be assessed monthly by a subject-completed food diary and phone assessments.

Conditions Studied

Study Locations (1)

North Carolina

  • University of North Carolina at Chapel Hill - Chapel Hill

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2012-10
Est. Completion 2015-10
Prema Menezes, PhD, PA-C

1 total trials

What the finished NCT01701895 record still lists

NCT01701895 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (91% lower).

The record links to 1 condition, with HIV-1-infection appearing as the primary indexed condition, and to 0 interventions.

NCT01701895 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT01701895 about?

NCT01701895 is a clinical study titled "Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera". The purpose of this research study is to evaluate how easy it is for female HIV- positive subjects taking Complera to comply with the dietary requirement using a food diary in the short term (4 weeks) and long term (24 weeks and 48 weeks) and to determine association between calorie intake and virol...

What is the current status of trial NCT01701895?

This trial is currently completed. The enrollment target is 33 participants. The study started on 2012-10. Estimated completion is 2015-10.

What conditions does trial NCT01701895 study?

This clinical trial studies the following conditions: HIV-1-infection.

Who is sponsoring clinical trial NCT01701895?

This trial is sponsored by Prema Menezes, PhD, PA-C, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01701895 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV-1-infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01701895's enrollment target sits among peer trials

33 55th of 71 higher than 16 of 71 other HIV-1-infection trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV-1-infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02861898 · 33 participants · Phase 1

    Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

  • NCT04871607 · 33 participants · Phase 2

    Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

  • NCT05071937 · 33 participants · Phase 2

    ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

  • NCT05168618 · 33 participants · Phase 2

    Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01701895, the US trial registry maintained by the National Library of Medicine. NCT01701895 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.